Autoantibodies Targeting Nephrin in Podocytopathies.
Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, Ronco P, Vivarelli M, Gesualdo L, Tomas NM, Huber TB; International Society of Glomerular Disease.
N Engl J Med. 2024 Aug 1;391(5):422-433. doi: 10.1056/NEJMoa2314471. Epub 2024 May 25.
Primary glomerulonephritides.
Floege J, Amann K.
Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25.
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J.
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
Advances in primary glomerulonephritis.
Ellison B, Cader R, Willcocks L.
Br J Hosp Med (Lond). 2024 Jul 30;85(7):1-11. doi: 10.12968/hmed.2024.0044.
Glomerulonephritis Histopathological Pattern Change.
AlYousef A, AlSahow A, AlHelal B, Alqallaf A, Abdallah E, Abdellatif M, Nawar H, Elmahalawy R.
BMC Nephrol. 2020 May 18;21(1):186. doi: 10.1186/s12882-020-01836-3.
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
El Karoui K, Fervenza FC, De Vriese AS.
J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29.
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants.
Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22.
Pathology of IgA nephropathy.
Roberts IS.
Nat Rev Nephrol. 2014 Aug;10(8):445-54. doi: 10.1038/nrneph.2014.92. Epub 2014 May 27.
Sparsentan: First Approval.
Syed YY.
Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.
The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
Chen Z, Li X, Li C, Cai J, Li H.
Kidney Int. 2024 Sep;106(3):540. doi: 10.1016/j.kint.2024.06.016.
